[Treatment costs in a medical intensive care unit: a comparison of 1992 and 1997].
OBJECTIVE
Treatment in an intensive care unit (ICU) is very expensive. Aim of this study was to determine the exact composition of costs and to analyse what factors are responsible for the rise in costs over the last 5 years.


METHODS
In a prospective investigation all 790 patients who had been treated at the ICU of the Medical Department of Frankfurt University during 1992 were included, findings being compared with data on all 208 patients treated in the ICU in May and June 1997. All important diagnostic and therapeutic measures were quantitatively determined each day.


RESULTS
The mean age of the ICU patients rose in the 5 years from 55 to 59 years (P < 0.001). Mean period of stay in the ICU remained unchanged (4.1 days), total duration of hospital stay (15 and 12 days, respectively), and treatment intensity (sum of points according to the "Therapeutic Intervention Scoring System" per ICU stay: 96 and 77, respectively). The mortality rate in the ICU fell from 16.3% to 10.6% (P = 0.02), hospital mortality rate from 23% to 14% (P = 0.01). Total cost rose from DM 797,860 to DM 1,148,945 per 100 patients (+44%). Of this total, personnel costs were DM 286,885 in 1992 and 356,091 in 1997 (+24%), costs for apparatus-based diagnostic and therapeutic tests were DM 169,743 and 245,156, respectively (+44%), DM 98,496 and 129,222 for drugs (+31%), and DM 60,399 and 186,671 (+209%) for blood and clotting products (in each category per 100 patients). Per case costs rose from DM 7970 to 11,489, per day costs from DM 1943 to 2831. 90% of cost increases were due to new strategies in the treatment of patients with myocardial infractions and those with severe clotting disorders and a rise in personnel costs.


CONCLUSIONS
The costs of a stay in the ICU has greatly increased over the last 5 years, the main causes being a change to new forms of treatment, especially in patients with myocardial infarction and those with haemophilia.
Klepzig
H
H
Zentrum der Inneren Medizin, Universität Frankfurt/Main. klepzig@em.uni-frankfurt.de
Winten
G
G
Thierolf
C
C
Kiesling
G
G
Usadel
K H
KH
Zeiher
A M
AM
D000328:Adult; D000367:Age Factors; D000368:Aged; D001688:Biological Products / Q000191:economics; D001778:Blood Coagulation Disorders / Q000191:economics / Q000628:therapy; D003365:Costs and Cost Analysis; D003422:Critical Care / Q000191:economics* / Q000706:statistics & numerical data; D019719:Diagnostic Equipment / Q000191:economics; D016527:Drug Costs; D004865:Equipment and Supplies, Hospital / Q000191:economics; D005858:Germany; D017048:Health Care Costs; D006785:Hospitals, University / Q000191:economics / Q000706:statistics & numerical data; D006801:Humans; D007362:Intensive Care Units / Q000191:economics* / Q000706:statistics & numerical data; D007388:Internal Medicine / Q000191:economics* / Q000706:statistics & numerical data; D007902:Length of Stay; D008875:Middle Aged; D009203:Myocardial Infarction / Q000191:economics / Q000628:therapy; D010564:Personnel, Hospital / Q000191:economics; D011446:Prospective Studies
D001688:Biological Products
Behandlungskosten auf einer medizinischen Intensivstation. Ein Vergleich von 1992 und 1997.